Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results covered the quarter ended March 31, 2026.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered the quarter ended March 31, 2026
- Press release issued May 12, 2026 and furnished as Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.